Trends of Antifungal Agent Susceptibility of Candida Strains Isolated from Blood Cultures in 2009–2018
Keywords:
Antifungal agent susceptibility, Blood culture, Candidemia, Candida bloodstream infections, Candida speciesAbstract
Candida is one of the most common causes of bloodstream infections and a leading cause of morbidity and mortality among hospitalized patients. The purpose of this study was to provide important information for formulating empirical treatment plans for candidemia by investigating the antifungal resistance rate of Candida. Among the Candida strains (973 cases) isolated from blood culture tests at Samsung Medical Center in 2009–2018, 4.7% (n = 44) comprising the Candida spp. (932 strains) showed resistance to fluconazole. The resistant strains included C. albicans, C. parapsilosis, C. tropicalis, and C. glabrata. In addition, Candida spp. (947 strains) showed resistance to amphotericin B (n = 6, 0.6%), flucytosine (n = 23, 2.4%) and voriconazole (n = 24, 3.1%). C. albicans was resistant to fluconazole (n = 23, 6.9%) and voriconazole (n = 21, 6.0%), The statistical analysis showed that C. albicans and non-albicans Candida species were resistant to fluconazole (P = 0.039) and voriconazole (P < 0.001). A monitoring system to understand the rate of candidiasis infections in a hospital setting is required. It is also important to make the right choice of antifungal agent based on drug susceptibility patterns. Therefore, an infection surveillance policy that tracks Candida resistance through regular antifungal susceptibility tests is necessary.
References
López Dupla M, Martínez JA, Vidal F, et al., Clinical Characterization of Breakthrough Bacteraemia: A Survey of 392 Episodes. J Intern Med, 258(2): 172–180. https://doi.org/10.1111/j.1365-2796.2005.01513.x
Goto M, Al-Hasan MN, 2013, Overall Burden of Bloodstream Infection and Nosocomial Bloodstream Infection in North America and Europe. Clin Microbiol Infect, 19(6): 501–509. https://doi.org/10.1111/1469-0691.12195
Trecarichi EM, Pagano L, Candoni A, et al., 2015, Current Epidemiology and Antimicrobial Resistance Data for Bacterial Bloodstream Infections in Patients with Hematologic Malignancies: An Italian Multicentre Prospective Survey. Clin Microbiol Infect, 21(4): 337–343. https://doi.org/10.1016/j.cmi.2014.11.022
Antinori S, Milazzo L, Sollima S, et al., 2016, Candidemia and Invasive Candidiasis in Adults: A Narrative Review. Eur J Intern Med, 34: 21–28. https://doi.org/10.1016/j.ejim.2016.06.029
Bassetti M, Righi E, Ansaldi F, et al., 2014, A Multicenter Study of Septic Shock Due to Candidemia: Outcomes and Predictors of Mortality. Intensive Care Med, 40: 839–845. https://doi.org/10.1007/s00134-014-3310-z
Wisplinghoff H, Bischoff T, Tallent SM, et al., 2004, Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study. Clin Infect Dis, 39(3): 309–317. https://doi.org/10.1086/421946
Kim JS, Gong SY, Kim JW, et al., 2019, Antimicrobial Susceptibility Patterns of Microorganisms Isolated from Blood Culture During the Last 8 Years: 2010~2017. Korean J Clin Lab Sci, 51(2): 155–163. https://doi.org/10.15324/kjcls.2019.51.2.155
Pappas PG, Kauffman CA, Andes DR, et al., 2016, Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis, 62(4): e1–e50. https://doi.org/10.1093/cid/civ933
Horn DL, Fishman JA, Steinbach WJ, et al., 2007, Presentation of the PATH Alliance® Registry for Prospective Data Collection and Analysis of the Epidemiology, Therapy, and Outcomes of Invasive Fungal Infections. Diagn Microbiol Infect Dis, 59(4): 407–414. https://doi.org/10.1016/j.diagmicrobio.2007.06.008
Kett DH, Azoulay E, Echeverria PM, et al., 2011, Candida Bloodstream Infections in Intensive Care Units: Analysis of the Extended Prevalence of Infection in Intensive Care Unit Study. Crit Care Med, 39(4): 665–670. https://doi.org/10.1097/CCM.0b013e318206c1ca
Colombo AL, Guimaraes T, Sukienik T, et al., 2014, Prognostic Factors and Historical Trends in the Epidemiology of Candidemia in Critically Ill Patients: An Analysis of Five Multicenter Studies Sequentially Conducted Over a 9-Year Period. Intensive Care Med, 40: 1489–1498. https://doi.org/10.1007/s00134-014-3400-y
Rex JH, Walsh TJ, Sobel JD, et al., 2000, Practice Guidelines for the Treatment of Candidiasis. Clin Infect Dis, 30(4): 662–678. https://doi.org/10.1086/313749
St-Germain G, Laverdière M, Pelletier R, et al., 2001, Prevalence and Antifungal Susceptibility of 442 Candida Isolates from Blood and Other Normally Sterile Sites: Results of a 2-Year (1996 to 1998) Multicenter Surveillance Study in Quebec, Canada. J Clin Microbiol, 39(3): 949–953. https://doi.org/10.1128/JCM.39.3.949-953.2001
Chakrabarti A, Sood P, Rudramurthy SM, et al., 2014, Incidence, Characteristics and Outcome of ICU-Acquired Candidemia in India. Intensive Care Med, 41: 285–295. https://doi.org/10.1007/s00134-014-3603-2
Cleveland AA, Harrison LH, Farley MM, et al., 2015, Declining Incidence of Candidemia and the Shifting Epidemiology of Candida Resistance in Two US Metropolitan Areas, 2008–2013: Results from Population-Based Surveillance. PLoS One, 10(3): e0120452. https://doi.org/10.1371/journal.pone.0120452
Hesstvedt L, Gaustad P, Andersen CT, et al., 2015, Twenty-Two Years of Candidaemia Surveillance: Results from a Norwegian National Study. Clin Microbiol Infect, 21(10): 938–945. https://doi.org/10.1016/j.cmi.2015.06.008
Vallabhaneni S, Mody RK, Walker T, et al., 2016, The Global Burden of Fungal Diseases. Infect Dis Clin North Am, 30(1): 1–11. https://doi.org/10.1016/j.idc.2015.10.004
Rex JH, Pappas PG, Karchmer AW, et al., 2003, A Randomized and Blinded Multicenter Trial of High-Dose Fluconazole plus Placebo versus Fluconazole plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic Subjects. Clin Infect Dis, 36(10): 1221–1228. https://doi.org/10.1086/374850
Lackner M, de Hoog GS, Verweij PE, et al., 2012, Species-Specific Antifungal Susceptibility Patterns of Scedosporium and Pseudallescheria Species. Antimicrob Agents Chemother, 56(5): 2635–2642. https://doi.org/10.1128/AAC.05910-11
World Health Organization, 2014, Antimicrobial Resistance: Global Report on Surveillance, viewed January 22, 2022, https://iris.who.int/bitstream/handle/10665/112642/9789241564748_eng.pdf
Pfaller MA, Diekema DJ, Jones RN, et al., 2001, International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol, 39(9): 3254–3259. https://doi.org/10.1128/JCM.39.9.3254-3259.2001
Chae MJ, Shin JH, Cho D, et al., 2003, Antifungal Susceptibilities and Distribution of Candida Species Recovered from Blood Cultures over an 8-Year Period. Korean J Lab Med, 23: 329–335.
Khan Z, Ahmad S, Al-Sweih N, et al., 2019, Changing Trends in Epidemiology and Antifungal Susceptibility Patterns of Six Bloodstream Candida Species Isolates Over a 12-Year Period in Kuwait. PLoS One, 14(5): e0216250. https://doi.org/10.1371/journal.pone.0216250
Rodriguez L, Bustamante B, Huaroto L, et al., 2017, A Multi-Centric Study of Candida Bloodstream Infection in Lima-Callao, Peru: Species Distribution, Antifungal Resistance and Clinical Outcomes. PLoS One 12(4): e0175172. https://doi.org/10.1371/journal.pone.0175172
World Health Organization, 2014, Antimicrobial Resistance: Global Report on Surveillance 2014 Summary, viewed January 14, 2022, https://iris.who.int/bitstream/handle/10665/112647/WHO_HSE_PED_AIP_2014.2_eng.pdf
Vallabhaneni S, Cleveland AA, Farley MM, et al., 2015, Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data from a Large Multisite Population-Based Candidemia Surveillance Program, 2008–2014. Open Forum Infect Dis, 2(4): ofv163. https://doi.org/10.1093/ofid/ofv163
Healey KR, Zhao Y, Perez WB, et al., 2016, Prevalent Mutator Genotype Identified in Fungal Pathogen Candida glabrata Promotes Multi-Drug Resistance. Nat Commun, 7: 11128. https://doi.org/10.1038/ncomms11128
Cho E-J, Shin JH, Kim SH, et al., 2015, Emergence of Multiple Resistance Profiles Involving Azoles, Echinocandins and Amphotericin B in Candida glabrata Isolates from a Neutropenia Patient with Prolonged Fungaemia. J Antimicrob Chemother, 70(4): 1268–1270. https://doi.org/10.1093/jac/dku518